Mankind Pharma to liquidate subsidiary BSVL, integrate its business
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board has approved the voluntary liquidation of Bharat Serums and Vaccines Limited (BSVL), its wholly owned subsidiary (96 percent held directly, 4 percent via Appian Properties). BSVL's business will transfer to Mankind Pharma on a going concern basis once approvals and license transfers are in place. Appian will receive cash for its 4 percent stake based on an independent valuation. No change in Mankind Pharma's shareholding pattern. The move aims to drive operational efficiency, cut compliance costs, and consolidate resources under one entity.
Internal consolidation; likely neutral to mildly positive as it simplifies group structure, cuts compliance costs, and brings BSVL's business fully onto Mankind Pharma's books.